Results 61 to 70 of about 2,655 (208)

Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies [PDF]

, 2020
© 2020 Eli Lilly and Company. Headache: The Journal of Head and Face Pain published by Wiley Periodicals LLC, on behalf of American Headache Society Objective: This post hoc analysis evaluated the efficacy of galcanezumab for the prevention of migraine ...
D’Souza, Deborah N., Lipsius, Sarah, Pearlman, Eric M., Schuh, Kory, Skljarevski, Vladimir, Smitherman, Todd A., Tietjen, Gretchen E.   +6 more
core   +1 more source

Post‐marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective Calcitonin gene‐related peptide (CGRP) inhibitors, including monoclonal antibodies (mAbs) and small‐molecule antagonists (gepants), have transformed migraine treatment. Although clinical trials established their efficacy and initial safety, post‐marketing surveillance is essential for understanding their real‐world safety profile in ...
Martina Giacon, Salvatore Terrazzino
wiley   +1 more source

Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials [PDF]

, 2023
Migraine; PreventionMigranya; PrevencióMigraña; PrevenciónBackground Several novel treatments targeting the calcitonin gene-related peptide pathway have been developed for migraine.
Garcia Azorin, David, Haghdoost, Faraidoon, Huessler, Eva-Maria, Messina, Roberta, Pozo Rosich, Patricia, Puledda, Francesca   +5 more
core   +1 more source

Delayed urticaria during treatment with anti‐CGRP monoclonal antibodies in migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To characterize clinical presentation and management of urticaria associated with calcitonin gene‐related peptide (CGRP) ‐targeting monoclonal antibodies (mAbs) for migraine prophylaxis. Background CGRP‐targeting mAbs are effective in migraine prophylaxis, but have been associated with hypersensitivity reactions, including urticaria.
Christoph T. Berger, Federico Burguet Villena, Severin B. Vogt, Lukas Heydrich, Karin Hartmann, Athina Papadopoulou   +5 more
wiley   +1 more source

Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine

Journal of Pain Research, 2021
Hisaka Igarashi,1 Mamoru Shibata,2 Akichika Ozeki,3 Kathleen Ann Day,4 Taka Matsumura3 1Department of Internal Medicine, Fujitsu Clinic, Kawasaki, Japan; 2Department of Neurology, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Japan; 3Eli ...
Igarashi H, Shibata M, Ozeki A, Day KA, Matsumura T   +4 more
doaj  

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine

The Journal of Headache and Pain, 2021
Background Galcanezumab, a humanized monoclonal antibody that binds calcitonin gene-related peptide, has demonstrated a significant reduction in monthly migraine headache days compared with placebo. Here, we analyze data from 3 randomized clinical trials
Michael Ament, Kathleen Day, Virginia L Stauffer, Vladimir Skljarevski, Mallikarjuna Rettiganti, Eric Pearlman, Sheena K. Aurora   +6 more
doaj   +1 more source

Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO‐CGRP study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study aimed to evaluate demographic characteristics, treatment effectiveness, and safety outcomes in patients with migraine undergoing anti‐calcitonin gene‐related peptide (CGRP) treatments regarding the presence of autoimmune diseases. Background CGRP has an important role in migraine pathophysiology through neuronal modulation
María Clara García‐Castillo, Álvaro Sierra‐Mencía, Edoardo Caronna, Daniel Toledo‐Alfocea, Alex Jaimes, Sarai Urtiaga, Javier Casas‐Limón, Albert Muñoz‐Vendrell, Sonia Santos‐Lasaosa, Valvanuz García Martín, Guillermo Martín Ávila, Marcos Polanco, Maria Dolores Villar‐Martínez, Cristina Trevino‐Peinado, Laura Rubio‐Flores, Antonio Sánchez‐Soblechero, Leonardo Portocarrero Sánchez, Elisa Luque‐Buzo, Alberto Lozano‐Ros, Ana Beatriz Gago‐Veiga, Javier Díaz‐De‐Terán, Andrea Recio García, Javiera Canales Rodríguez, Andrea Gómez García, Marta González Salaices, Sergio Campoy, Ane Mínguez‐Olaondo, Stefania Maniataki, Vicente González‐Quintanilla, Jesús Porta‐Etessam, María‐Luz Cuadrado, Ángel Luis Guerrero Peral, Patricia Pozo‐Rosich, Jaime Rodríguez‐Vico, Mariano Huerta‐Villanueva, Julio Pascual, Peter J. Goadsby, Alicia Gonzalez‐Martinez   +37 more
wiley   +1 more source

Galcanezumab modulates Capsaicin-induced C-fiber reactivity

Cephalalgia, 2022
Background The vasodilatory calcitonin-gene related peptide (CGRP) is understood as pivotal mediator in migraine pathophysiology. Blocking CGRP with small molecules or monoclonal antibodies (CGRP-mAb) reduces migraine frequency. However, prescription of CGRP-mAbs is still regulated and possible predictive measures of therapeutic success would be useful.
Hauke Basedau, Thalea Oppermann, Elisa Gundelwein Silva, Kuan-Po Peng, Arne May   +4 more
openaire   +2 more sources

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3‐Month results from the TRIUMPH study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To compare the 3‐month effectiveness of galcanezumab with select traditional oral migraine preventive (TOMP) medications recommended by scientific societies (TOMP efficacy subset) and with the most frequently used individual TOMP medications.
Shivang Joshi, Cristina Tassorelli, Manjit Matharu, Taoufik Alsaadi, Carlos Vallarino, Lars Viktrup, Maurice Vincent, Rebecca L. Robinson   +7 more
wiley   +1 more source

Biopharmaceuticals for Cancer Treatment: An Update

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath, Yousuf Alam, Afsana Mustak Mim, Maksuda Akter, Mohammad Abbas Gani, Khondaker Muhammad Khairul Alam, Md. Nur Alam   +6 more
wiley   +1 more source